×
About 1,250 results

ALLMedicine™ Gastrointestinal Hemorrhage Center

Research & Reviews  357 results

Signet-ring cell carcinoma of the duodenal bulb presenting with gastrointestinal hemorr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087945
BMC Gastroenterology; Ye N, Bao X et. al.

May 10th, 2022 - Primary duodenal cancer (PDC) is rare, especially signet-ring cell carcinoma (SRCC) of the duodenal bulb, and it is commonly misdiagnosed as an ulceration. Here, we report a rare case of SRCC of the duodenal bulb presenting with gastrointestinal h...

Gastrointestinal Hemorrhage After Antidepressant Drug Use: A Case Report.
https://doi.org/10.1097/JCP.0000000000001546
Journal of Clinical Psychopharmacology; Huang H, Zhang P et. al.

May 1st, 2022 - Gastrointestinal Hemorrhage After Antidepressant Drug Use: A Case Report.|2022|Huang H,Zhang P,Wu L,Lai J,Hu S,|adverse effects,chemically induced,complications,

Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.
https://clinicaltrials.gov/ct2/show/NCT04174989

Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...

Gastrointestinal hemorrhage as an acute-on-chronic liver failure trigger in cirrhotic p...
https://doi.org/10.17219/acem/147464
Advances in Clinical and Experimental Medicine : Official... Rogalski P, Zaborowska M et. al.

Apr 20th, 2022 - Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and very high short-term mortality. To assess the incidence and factors predisposing to ACLF in patie...

see more →

Guidelines  1 results

Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Soc...
https://doi.org/10.1055/s-0034-1393172
Endoscopy Gralnek IM, Dumonceau JM et. al.

Sep 30th, 2015 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH). Main Recommendations MR1. ESGE recommends im...

see more →

Drugs  58 results see all →

Clinicaltrials.gov  13 results

Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.
https://clinicaltrials.gov/ct2/show/NCT04174989

Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...

Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
https://clinicaltrials.gov/ct2/show/NCT01717599

May 4th, 2021 - The study described in this report will be approved by the ethics committee of Yonsei University School of Medicine, Seoul, Korea. Between July 2012 and February 2013, 380 patients fulfilled the inclusion criteria, 380 of whom were included in the...

Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage
https://clinicaltrials.gov/ct2/show/NCT04184934

Jul 21st, 2020 - Specific aims of this study : To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis. To investigate the ability of novel biomarkers to predict the de...

Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
https://clinicaltrials.gov/ct2/show/NCT03812705

Apr 20th, 2020 - The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD). Inclusion criteria: Age>= 14 yrs ≤60 yrs. Di...

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
https://clinicaltrials.gov/ct2/show/NCT04264260

Feb 11th, 2020 - Study procedures Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the rig...

see more →

News  71 results

Gynecologic Oncologists Continue to Pursue Novel Agents, Immunotherapy in Ovarian Cancer
https://www.onclive.com/view/gynecologic-oncologists-continue-to-pursue-novel-agents-immunotherapy-in-ovarian-cancer

Oct 6th, 2021 - The ovarian cancer armamentarium continues to evolve with novel agents, such as antibody-drug conjugates (ADCs) and immunotherapy, even with clinical trial findings showing mixed, yet intriguing, results with these classes of agents. In a prese...

Real-World Data Suggest Unmet Need for Effective Post-BTK Inhibitor Options in MCL
https://www.onclive.com/view/real-world-data-suggest-unmet-need-for-effective-post-btk-inhibitor-options-in-mcl

Aug 18th, 2021 - For patients with mantle cell lymphoma (MCL) who have progressed after treatment with a BTK inhibitor such as ibrutinib (Imbruvica), there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal ou...

Glofitamab Demonstrates Durable Responses in Relapsed/Refractory B-Cell Lymphoma
https://www.onclive.com/view/glofitamab-demonstrates-durable-responses-in-relapsed-refractory-b-cell-lymphoma

Apr 21st, 2021 - The novel T-cell–engaging bispecific antibody glofitamab (RO7082859) demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive...

Updated Cabozantinib Data Includes 6 Patient Deaths
https://www.onclive.com/view/updated-cabozantinib-data-includes-6-patient-deaths

Dec 20th, 2020 - Nicholas J. Vogelzang, MD Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO’s annual meeting. The fatalities had not been reported with the c...

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma
https://www.onclive.com/view/atezolizumab-plus-vemurafenib-cobimetinib-impresses-in-braf-v600-melanoma

Dec 20th, 2020 - Grant A. McArthur, MBBS, PhD Treatment with atezolizumab (Tecentriq) in combination with vemurafenib (Zelboraf) and cobimetinib (Cotellic) was found to significantly improve progression-free survival (PFS) and produce durable responses versus vem...

see more →